Major initiative to bring advanced therapies from research to patients in Skåne

Backed by SEK 36 million, key stakeholders in Skåne are joining forces in a major initiative to take advanced therapies from research to patients and to develop and commercialise cutting-edge research in ATMP – Advanced Therapy Medicinal Products. The aim is to accelerate the next generation of groundbreaking therapies so that more potentially life-saving ATMP treatments can reach patients who currently lack effective treatment options.

The project, ATMP Path2Patient, is led by Lund University’s innovation office, LU Innovation, and carried out in collaboration with SmiLe Venture Hub, Medicon Village Innovation, the ATMP facility at Lund University (LU-ATMP), and Region Skåne’s ATMP Centre. The majority of the funding comes from the Swedish Agency for Economic and Regional Growth (Tillväxtverket) and Region Skåne.

The purpose is to proactively support academic projects through interdisciplinary review processes, where strategically important decisions are identified and made early in the development phase, increasing the likelihood that new treatments will ultimately benefit patients.

In addition to strengthening innovation and commercialisation support, the project will also develop new technical platforms and materials for the manufacturing of cell and gene therapies, within so-called pre-GMP and GMP production. This will significantly simplify the transition from research to clinic and open new opportunities for emerging therapies. The long-term goal is for more ATMP projects to improve and save lives.

More information in press release (in Swedish) in our press room.